Why Walking Pneumonia Surges Every Three to Seven Years

Every three to seven years, without much warning, cases of walking pneumonia climb across the country, fill pediatric waiting rooms, and then recede again. The Centers for Disease Control and Prevention has been tracking the most recent cycle since 2023, when the bacteria behind it, Mycoplasma pneumoniae, began re-emerging globally after a prolonged pandemic-era lull. The pattern is not random. CDC's own surveillance page states it plainly: "There are usually peaks of disease every 3 to 7 years. Variation in strain types contributes to this pattern."

What is walking pneumonia, exactly?

It is a mild-to-moderate lung infection caused by Mycoplasma pneumoniae, a bacterium so structurally unusual — it has no cell wall — that the antibiotics doctors reach for first against ordinary pneumonia do not work on it. Amoxicillin and other penicillin-type drugs are ineffective; macrolides such as azithromycin are the standard treatment instead, according to the CDC. The nickname comes from how mild it usually looks: symptoms build gradually, and people often keep going to school or work with what feels like a stubborn cold, even once the infection has progressed to pneumonia.

Why does it cycle over years instead of every winter, like the flu?

Because population-level immunity works like a slowly draining reservoir rather than a seasonal reset. After infection, people build some immunity to the strain that infected them, but that protection fades over a few years and does not fully cover other circulating strain types. As enough people's immunity wanes and new strains rotate in, the bacteria find a large enough pool of susceptible people to spread widely again, and case counts fall once more as immunity rebuilds. That is a different mechanism than the one driving this year's redesigned flu shot, which chases mutating strains every single season; Mycoplasma's rhythm runs on population immunity fading over years, closer in spirit to why measles keeps finding unvaccinated pockets to reignite in, just without a vaccine to blame the gaps on — there isn't one for Mycoplasma.

How big was the most recent surge?

Large enough to change who doctors expected to see sick. CDC tracking of emergency-department visits found diagnosed Mycoplasma infections climbed steadily through the summer of 2024, peaking in August among both 2-to-4-year-olds and 5-to-17-year-olds. The increase among children under 5 stood out specifically because walking pneumonia has historically been considered a school-age and teenage illness. NPR spoke with pediatricians who watched the shift firsthand: Caleb Ward, a pediatric emergency medicine physician at Children's National Hospital in Washington, D.C., said cases there were running roughly tenfold above normal at the peak. Folks historically may have been going to school, going to work, assuming they just had a kind of mild, cold virus and in fact, had mycoplasma pneumonia, Ward told NPR.

Is walking pneumonia still elevated right now?

Partially. CDC's most recent update on the outbreak, last reviewed in May 2026, says infections have been trending down nationally since the start of 2025 — but adds that levels "remain elevated in some regions of the United States in 2025 and into 2026," meaning the multi-year cycle is winding down unevenly rather than dropping to a low baseline everywhere at once. That is consistent with how these waves have historically ended: gradually, and later in some places than others, rather than all at once.

Does drug resistance make this cycle more dangerous?

It is a real and growing complication, though not yet a US-specific crisis. Macrolide-resistant Mycoplasma has been rising worldwide since the early 2000s, and CDC estimates overall global resistance around 28%, a figure that hides enormous regional variation: roughly 80% of cases in China test resistant, versus more than 50% in Japan, about 12% in Canada, around 5% across Europe, and less than 10% in the United States overall. American clusters and localized outbreaks have occasionally shown resistance above 20%, which is why doctors who suspect an infection is not responding to a standard macrolide are advised to consider a second-line drug rather than assume the diagnosis is wrong.

None of this means every lingering cough this fall is walking pneumonia, or that this year is guaranteed to be a peak year — the reservoir-and-rebuild cycle CDC describes does not run on a fixed calendar, just a three-to-seven-year range. What the pattern does explain is why a disease with no vaccine and no national reporting requirement can vanish from the headlines for years and then reappear as if from nowhere: it never actually left. It was just waiting for enough of the population's immunity to fade.